Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Kroger Co (KR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Kroger Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.69 (market cap $29.60B), while Kroger Co trades at $56.16 (market cap $34.46B). The key difference: Kroger Co is the larger of the two by market cap, and Kroger Co pays a 2.56% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | KR | |
|---|---|---|
Market Cap | $29.60B | $34.46B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $75.60 |
52-Week Low | $205.48 | $55.53 |
Enterprise Value | $27.56B | $54.56B |
Dividend Yield | — | 2.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Kroger (KR) trades at $56.15, down 0.58% on the day, reflecting recent market pressure. The stock shows mixed signals with a bearish technical outlook but solid fundamentals including a low P/S ratio of 0.24 and consistent dividend payments. Recent earnings saw a Q1 2026 miss but beats in prior quarters, while analyst consensus remains positive with a $68.25 price target. Cash flow from operations remains strong at $5.79B in 2025, supporting ongoing investments in e-commerce and digital initiatives.
The outlook for KR is cautiously optimistic. Valuation appears reasonable relative to sales, and dividend income provides stability. However, near-term risks include competitive pressures in grocery retail, margin compression from inflation, and technical bearish signals. Investors should weigh strong cash generation against earnings volatility and debt levels that have risen to 30.23% of assets in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
